As part of the licensing agreement, Novartis Spark Therapeutics will pay $105 million in cash as an advance fee. Spark Therapeutics is entitled to receive up to $65 million in cash milestone payments, based on short-term approval from the European Regulatory Authority (EMA) and first sales outside the U.S. in certain markets. Spark Therapeutics Also Entitled to Obtain License Payments on Neparvovec`s Net Sales Outside the U.S. PHILADELPHIA, Jan. 24, 2018 (GLOBE NEWSWIRE) — Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company committed to addressing the inevitability of genetic diseases, today announced that it has entered into a licensing agreement with Novartis Pharmaceuticals for the development and commercialization of Neparvovec outside the United States. while Spark Therapeutics will continue to exclusively distribute LUXTURNA™ (previously neparvovec-ryzl) in the United States. Nor can it be guaranteed that we will achieve some or all of the intended objectives of one or both of the licensing, manufacturing and supply agreements, or that such agreements will be economically successful. . . .